NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Subscribe To Our Newsletter & Stay Updated
